6Z4.F Stock Analysis
6Z
Uncovered
Crinetics Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Crinetics Pharmaceuticals, Inc. operates as a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company is headquartered in San Diego, California and currently employs 210 full-time employees. The company went IPO on 2018-07-18. The firm is focused on the discovery, development and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. The company has discovered a pipeline of oral nonpeptide chemical entities that target peptide G protein coupled receptors (GPCRs) to treat a rare endocrine disease. Its product candidates include paltusotine, CRN04777 and CRN04894. Its paltusotine is in clinical development for the treatment of acromegaly and neuroendocrine tumors. CRN04777 is an investigational, oral, nonpeptide somatostatin receptor type 5 (SST5), agonist designed for the treatment of congenital hyperinsulinism (HI). CRN04894 is an investigational, oral, nonpeptide product candidate designed for the treatment of diseases caused by excess adrenocorticotrophic hormone (ACTH), including Cushings disease, congenital adrenal hyperplasia (CAH), and Ectopic ACTH Syndrome (EAS).